In the crowded world of liquid biopsy, Inivata operates like a stealth fighter: 104 employees generating $16.1M annually with a war chest of $164.4M in funding. This isn't a startup burning cash on marketing—it's a precision instrument honing in on the $50B oncology diagnostics market.

"Inivata isn't playing the volume game—it's playing the precision game. With 104 employees, they're generating $155K per employee in revenue, a metric that speaks to surgical efficiency in a sector known for massive burn rates."

The absence of traffic data isn't a weakness—it's a feature. Inivata.com's near-zero web presence suggests a company focused on clinical channels, not direct-to-consumer marketing. Their customers aren't browsing websites; they're oncologists in hospital systems making evidence-based purchasing decisions. This is enterprise sales at its most sophisticated.

• 104 employees = lean clinical operations, not bloated commercial teams
• $16.1M revenue = validated clinical utility, not speculative growth
• $164M funding = staying power for long clinical trials
• Scientific leadership = IP-first strategy over market-first strategy